Title:
TRANSDERMAL OR TRANSMUCOSAL DOSAGE FORMS WITH A NICOTINE-CONTAINING ACTIVE SUBSTANCE COMBINATION FOR SMOKER DISINTOXICATION
Document Type and Number:
WIPO Patent Application WO2001080837
Kind Code:
A3
Abstract:
The invention relates to a transdermal or transmucosal pharmaceutical dosage form for the treatment of nicotine dependence or for smoker disintoxication, containing nicotine, a nicotine salt, a nicotine derivative or a substance with a nicotinic effect in combination with at least one additional active substance. The invention is characterized in that it contains at least one substance affecting the central nervous system as additional active substance(s).
Inventors:
THEOBALD FRANK (DE)
FRICK ULRICH (DE)
FRICK ULRICH (DE)
Application Number:
PCT/EP2001/003712
Publication Date:
February 21, 2002
Filing Date:
April 02, 2001
Export Citation:
Assignee:
LOHMANN THERAPIE SYST LTS (DE)
THEOBALD FRANK (DE)
FRICK ULRICH (DE)
THEOBALD FRANK (DE)
FRICK ULRICH (DE)
International Classes:
A61K9/00; A61K9/70; A61K31/465; A61K45/00; A61K45/06; A61K47/32; A61K47/36; A61K47/38; A61P25/00; A61P25/02; A61P25/18; A61P25/24; A61P25/26; A61P25/34; (IPC1-7): A61K9/70; A61K31/465
Domestic Patent References:
| WO1996000072A1 | 1996-01-04 | |||
| WO2000016762A2 | 2000-03-30 |
Other References:
CHEMICAL ABSTRACTS, vol. 133, no. 16, 16 October 2000, Columbus, Ohio, US; abstract no. 227747n, page 1120; XP002155650
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; D. JORENBY ET AL.: "a controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation", XP002180625
DATABASE BIOSIS BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; D. JORENBY ET AL.: "a controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation", XP002180625
Download PDF:
Previous Patent: USE OF PARTICULATE VECTORS IN IMMUNOMODULATION
Next Patent: USE OF N2-SUBSTITUTED BENZ[F]INDAZOLE-4,9-QUINONES AS ANTIPARASITIC AGENTS
Next Patent: USE OF N2-SUBSTITUTED BENZ[F]INDAZOLE-4,9-QUINONES AS ANTIPARASITIC AGENTS